# Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

> **NCT00009763** · PHASE1 · UNKNOWN · sponsor: **University of California, Davis**

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** monoclonal antibody m170
- **DRUG:** cyclosporine
- **DRUG:** paclitaxel
- **PROCEDURE:** peripheral blood stem cell transplantation
- **RADIATION:** yttrium Y 90 monoclonal antibody m170

## Key facts

- **NCT ID:** NCT00009763
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2001-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00009763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00009763, "Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00009763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*